Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Given the substantial variability in clinical AI algorithms, implementing effective monitoring solutions is highly recommended.

Easily available nitrous oxide canisters like "Whip-it!" can cause both temporary and lasting neurological damage or death.

Doctors in New York used a stem cell therapy to cure sickle cell anemia for the first time by modifying red blood cell production.

Presbyopia-correcting contact lenses still evade a significant number of patients with presbyopia, even as prescription rates have increased.

The FDA has accepted for review the New Drug Application for SYD-101 (atropine sulfate) to slow the progression of myopia in children.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

Minimally invasive glaucoma surgeries offer an alternative to glaucoma drops, which, in some cases, do not adequately lower IOP and show poor compliance.

Sexual satisfaction is negatively impacted by living with Sjögren disease and is strongly correlated with depressive symptoms.

Upward telemedicine trends in schizophrenia treatment were rapid after the COVID-19 pandemic, particularly in state-operated agencies.

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050.